Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Target in Sight: Escalating Therapy to Reach LDL-C Goals
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Bridging ASCVD Care Between Academic and Rural Settings
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
prof. Hiddo Heerspink
Jennifer B. Green, MD
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC
Piotr Ponikowski, MD, PhD, FESC, FHFA
Improving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
Early Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Akshay S. Desai, MD
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Jonathan Cunningham, MD
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
John Ostrominski
FINE-HEART Pooled Analysis
Maria Pabon
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.